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Abstract
The a4 integrin antagonist natalizumab was shown to be effective in patients with immune-mediated disorders but was
unexpectedly associated with JC polyomavirus associated progressive multifocal leukoencephalopathy (PML) in two
multiple sclerosis (MS) and one Crohn’s disease patients. Impaired immune surveillance due to natalizumab treatment may
have contributed to the JCV reactivation. As HHV-6 has been suggested to play a role in MS, we asked whether this virus
could also have been reactivated during natalizumab therapy. Matched sera and CSF from a limited set of MS patients
treated with and without natalizumab were examined for evidence of HHV-6. In addition, we also superinfected a persistent
JC virus infected glial cell with HHV-6A to determine if JC virus can be increased. Elevated serum HHV6 IgG and HHV-6A DNA
was detected in the CSF of a subset of patients but not controls. We confirmed that superinfection with HHV-6 of a JC virus
infected glial cells increased expression of JCV. These results support the hypothesis that treatment with natalizumab may
be associated with reduced immune surveillance resulting in reactivation of viruses associated with MS pathogenesis.
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Introduction
Multiple sclerosis (MS) is an immune mediated demyelinating
disorder of the central nervous system (CNS) characterized by
inflammatory lesions in the brain and spinal cord that result in
varying degrees of neurological impairment. Self-reactive lympho-
cytes are believed to play a role in the pathogenesis of MS [1]. To
access the central nervous system (CNS), cells must cross the
blood-brain barrier by binding to adhesion molecules present on
vascular endothelial cells. Thus, inhibiting access of these
inflammatory cells to the CNS by interference with molecules
involved in vascular adhesion is an attractive therapeutic target.
Natalizumab, is a humanized monoclonal antibody against the a4
subunit of a4b1 and a4b7 integrins, which are molecules involved
in cell motility through interaction with ligands in the extracellular
matrix. Natalizumab blocks the interaction of these molecules with
their receptors, vascular-cell adhesion molecule 1 (VCAM-1) and
mucosal addressin-cell adhesion molecule 1, present on the
vascular endothelium resulting in decreased migration of periph-
eral inflammatory cells into the target tissues [2,3].
While natalizumab was shown to be clinically effective in
patients with relapsing-remitting MS in two phase III clinical trials
(US FDA. Natalizumab (marketed as Tysabri) Information. http:
//www.fda.gov/cder/drug/infopage/natalizumab/default.htm
(2005)), it was unexpectedly associated with a rare neurological
complication in two patients with MS and one with Crohn’s
disease who developed progressive multifocal leukoencephalopa-
thy (PML) [4,5,6]. Two patients subsequently died [7,8] and
natalizumab was voluntarily withdrawn from the market. PML is a
CNS opportunistic infection caused by reactivation of a clinically
latent JC polyomavirus that infects and destroys oligodendrocytes
leading to multifocal areas of demyelination and associated
neurologic dysfunction [9]. PML invariably occurs in the context
of impaired cell-mediated immunity most frequently observed in
individuals with compromised immune systems. One mechanism
suggested to explain the relationship between natalizumab
treatment and development of PML is that by blocking a4
integrin and thus decreasing lymphocyte trafficking to the brain
[10], the normal immune surveillance in the brain was reduced,
allowing the reactivation of latent viruses present in the nervous
system [11]. In support of this hypothesis, we recently reported
that the CD4:CD8 ratio in the CSF of MS patients treated with
natalizumab was reduced to levels similar to that observed in HIV
infection [12].
If impaired immune surveillance in the brain following
natalizumab treatment is associated with JCV reactivation, there
is no reason to believe, a priori, that such a mechanism would be
specific for JCV and thus such impaired surveillance could result
in the reactivation of other latent CNS viruses. Human
herpesvirus-6 (HHV-6) is a pleiotropic b-herpesvirus that has
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virus have been described[15]. HHV-6B is the etiologic agent of
the childhood disease exanthem subitum (roseola)[16] while the
HHV-6A variant is considered more neurotropic with distinct host
cell tropisms[17]. Like JCV, HHV-6 establishes latency in the host
and can be reactivated under conditions of immunosuppression.
Moreover, there is a large body of literature that has postulated a
role for HHV-6 in the pathogenesis of MS [18,19,20,21,22,
23,24,25,26,27]. Studies have consistently reported increased
antibody responses to HHV-6 proteins in MS patients, demon-
strated the presence of HHV-6A DNA in serum (indicative of a
productive infection), particularly during clinical exacerbations,
and pathologically HHV-6 is more often detected in regions of MS
plaques compared to normal appearing white matter. Interesting-
ly, HHV-6 has also been associated with PML. HHV-6 and JCV
have been detected in white matter both within and surrounding
PML lesions and in intralesional oligodendrocytes [28].
Based on the previously established associations of HHV-6 with
MS and the unexpected reactivation of latent virus in natalizu-
mab-treated patients, we asked whether HHV-6 might also be
reactivated in MS patients treated with natalizumab. We
examined sera and matched CSF from a cohort of MS patients
who received natalizumab compared to MS patients with clinically
definite MS not treated with natalizumab. Detection of cell-free
HHV-6A DNA sequences (the more neurotropic HHV-6 variant
more often associated with MS) in CSF and increased frequency of
serum HHV-6 specific antibodies in natalizumab treated MS
patients suggest that reactivation of HHV-6 may also be associated
with natalizumab therapy. While the relationship of natalizumab
therapy with HHV-6 and JCV-PML is unclear, we also
demonstrate that, in vitro, HHV-6 significantly augments the
replication of JCV. These results suggest a possible mechanism
whereby natalizumab treatment may reactivate latent viruses of
the CNS (such as HHV-6) that can subsequently induce the
replication of other viruses (such as JCV) that have been associated
with catastrophic outcomes (PML) in a small subset of patients.
Results
Detection of HHV-6 DNA in CSF from natalizumab-
treated MS patients
Using nested PCR for the HHV-6 U57 gene, cell-free viral
DNA was detected in 2 out of 23 natalizumab-treated patients at
UT Southwestern (Figure 1). Sample TY2 was positive on the
initial screen of CSF from natalizumab treated MS patients while
sample TY3 was positive from a follow-up CSF sample obtained 4
months after the first lumbar puncture that was HHV-6 negative.
In contrast, HHV-6 viral sequences were not detected in 16
samples from non-natalizumab treated MS patients collected at
the same center, consistent with our inability to detect HHV-6
DNA in CSF from 31 NIH MS patients and 16 control patients
with other neurological disorders (as summarized in table 1). The
number of natalizumab-treated patients positive for HHV-6 DNA
in CSF was obviously too small to achieve statistical significance in
relation to non-natlizumab treated MS patients from the same
center (Table 1). However, given the limited number of patients
and our experience with the detection of HHV-6 in CSF (Table 1),
detection of low levels of HHV-6 in the CSF of MS patients
treated with natalizumab was unexpected.
It was also critical to determine which variant of HHV-6 was
detected in CSF of natalizumab-treated MS patients. DNA
sequencing of the amplified HHV-6 U57 gene (data not shown)
from both CSF-positive natalizumab-treated MS patients showed
99% identity to the HHV-6A U1102 variant as represented by the
results in figure 1 for patient TY2 (Figure 1). These results confirm
the observation that amplifiable HHV-6 sequences were detected in
CSF of natalizumab-treated MS patients and subtyped as HHV-6A,
the variant more frequently associated with MS [18,22,24].
Increased anti-HHV-6 IgG in serum and CSF of MS
patients
Previous work from our group demonstrated, by ELISA, that
there was no statistically significant difference in the amount of anti-
HHV-6 IgG in the serum of MS patients versus normal donors or
other inflammatory and other neurological disease controls [24].
Here, we examined sera from 19 normal donors and 23 untreated
MS patients (a subset of the NIH cohort) for serum IgG against
HHV-6 using the HHV-6 ECL assay. Values obtained with this
assay were normalized to total serum IgG for each patient. As
predicted, figure 2A shows no statistically significant difference in
anti-HHV-6 serum IgG between the two groups although several
MS patients demonstrated levels of serum IgG in excess of the
empirically defined ‘‘normal range’’, operationally defined as 3
standard deviations above the mean for all normal sera.
The presence of anti-HHV-6 IgG in CSF has been reported in
MS, particularly during exacerbations [29,30]. We compared anti-
HHV-6 IgG levels in the CSF between other neurologic disease
controls (OND, Table S1), patients with suspected viral encephalitis,
untreated MS patients (a subset of the NIH cohort), and patients
with infectious complications post-bone marrow transplant (BMT)
[31]. ‘Normal range’ for HHV-6 IgG in CSF was defined as 3
standard deviations above the mean for CSF of patients with OND
(Figure 2B). As positive controls, CSF from patients with encephalitis
and neurologic disease post (BMT) were used since subsets of these
patients have been reported to be reactive for HHV-6 [31,32,33].
This observation was confirmed using our novel HHV-6 ECL assay
in CSF from the above patient cohorts, demonstrating statistically
elevated levels of HHV-6 IgG in post-BMT CSF compared to
control OND CSF (Figure 2B). Similarly, untreated MS patients
exhibited significantly higher levels of anti-HHV-6 IgG in the CSF
compared to control OND CSF, consistent with previous results
demonstrating elevated HHV-6 antibody titers in CSF of MS
patients [24]. Collectively, these results help to characterize the
HHV-6 ECL assay as a reliable and robust method for the detection
of HHV-6 IgG in serum and CSF.
Figure 1. Detection of HHV-6A DNA in CSF of natalizumab-
treated MS patients. Representative figure of nested PCR detection
for HHV-6 in CSF and sera of UT-MS patients. Lane 54 = PCR detection
in CSF sample of a natalizumab treated patient TY2. NS = known
negative serum control; NTC = no template control; NC = known CSF
control; PC = CSF positive control; PS = known serum positive control;
P = positive control (HHV-6B Z29 infected SupT-1cells).
doi:10.1371/journal.pone.0002028.g001
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natalizumab-treated MS patients
Based on the earlier reports of HHV-6 with both MS and PML
[28], and the results in this study detecting HHV-6A DNA
sequences in a subset of natalizumab treated MS patients
(Figure 1), we investigated whether differential antibody responses
between MS patients treated with and without natalizumab could
be demonstrated. HHV-6 IgG levels were measured in serum
from all 23 natalizumab-treated MS patients and 17 MS patients
from the same center (UT Southwestern) who did not receive
natalizumab (Table 1). As shown in figure 3A, natalizumab-treated
MS patients had significantly higher levels of serum HHV-6 IgG
than MS patients not treated with natalizumab. Serum HHV-6
IgG levels from the UT Southwestern non-natalizumab treated
MS patients were similar to the non-natalizumab treated NIH MS
cohort (Figure 3A; p= .78). Analysis of HHV-6 IgG in CSF
samples was also performed. As we have shown that CSF HHV-6
IgG was elevated in non-natalizumab treated MS groups
compared to CSF from patients with OND (Figure 3B), there
was still a trend towards higher levels of CSF HHV-6 IgG in a
Table 1. UT Texas Natalizumab treated and Untreated MS
Patients.
Patient Age
1 Gender Diagnosis EDSS
2 Clinical Trial
Natalizumab Treated Patients
TY1 41 Male RRMS/1998 1.5 N/A
3
TY2 48 Female RRMS/1990 4.5 AFFIRM
4
TY3 51 Female RRMS/2001 0 AFFIRM
TY4 46 Female RRMS/1994 4.5 AFFIRM
TY5 37 Female RRMS/1992 0 AFFIRM
TY6 53 Female RRMS/2002 4 AFFIRM
TY7 38 Female RRMS/1995 3.5 AFFIRM
TY8 42 Female RRMS/1999 1.5 SENTINEL
5
TY9 46 Female RRMS/1999 3.5 SENTINEL
TY10 50 Female RRMS/1995 2.5 SENTINEL
TY11 53 Female RRMS/1994 6 SENTINEL
TY12 52 Female RRMS/1989 2.5 SENTINEL
TY13 35 Female RRMS/1992 1.5 SENTINEL
TY14 51 Female RRMS/1999 1.5 SENTINEL
TY15 46 Male RRMS/1996 4 SENTINEL
TY16 31 Female RRMS/2000 1.5 SENTINEL
TY17 35 Female RRMS/1992 1.5 SENTINEL
TY18 45 Female RRMS/1996 3.5 SENTINEL
TY19 45 Female RRMS/1999 2.5 SENTINEL
TY20 31 Female RRMS/1999 2 SENTINEL
TY21 43 Female RRMS/2001 2 SENTINEL
TY22 54 Male RRMS/2001 1.5 SENTINEL
TY23 51 Female RRMS/2001 3.5 SENTINEL
Untreated or Non-Natalizumab Treated Patients
UTMS24 44 Female PPMS/2000 6 none
UTMS25 26 Female RRMS/2005 1.5 none
UTMS26 60 Female PPMS/1999 6 none
UTMS27 58 Female PPMS/1996 ND none
UTMS28 63 Male SPMS/1977 ND cellcept and
avonex
UTMS29 58 Male PPMS/2000 6 none
UTMS30 48 Male PPMS/2000 ND none
UTMS31 62 Male CIS-ON/2005 ND none
UTMS32 61 Female PPMS/2001 3 none
UTMS33 49 Male PPMS/2002 6 none
UTMS34 35 Female RRMS/2001 ND betaseron
UTMS35 66 Male PPMS/1991 4 none
UTMS36 37 Male PPMS/2004 3.5 none
UTMS37 42 Male PPMS/2000 4.5 none
UTMS38 32 Female RRMS/2002 ND none
UTMS39 53 Female SPMS/1994 ND avonex
UTMS40 47 Male PPMS/2000 3.5 none
1Age assessed at time of enrollment in this study.
2EDSS assessed at time of enrollment in this study.
3N/A = Not applicable. Patient started natalizumab after initial approval by the
Food and Drug Administration.
4AFFIRM = Natalizumab safety and efficacy in relapsing remitting multiple
sclerosis.
5SENTINEL = The safety and efficacy of natalizumab in combination with
interferon beta-1a in patients with relapsing-remitting multiple sclerosis RRMS
= relapsing-remitting multiple sclerosis; PPMS = primary progressive multiple
sclerosis; SPMS = secondary progressive multiple sclerosis; CIS-ON = clinically
isolated syndrome/optic neuritis; ND = not determined.
doi:10.1371/journal.pone.0002028.t001
Figure 2. Detection of anti-HHV-6 IgG in serum and CSF of MS
patients. (A) HHV-6 antibody in sera of 19 healthy controls (ND) and 23
NIH MS patients without natalizumab treatment. Normalized signal
calculated as reactivity on [(HHV-6B infected lysate - uninfected cells)/
total human IgG]. Normal range is 3 standard deviations (SD) above the
mean normalized signal (2872) of ND. (B) Comparison of HHV6 reactivity
in CSF from other neurologic controls (OND), encephalitis (Enceph.),
untreated NIH MS patients (NIH-MS-Nat (2)) and BMT recipients with
neurologic complications. HHV6 reactivity measured as photon
emission on HHV-6B virus infected lysate minus emission on uninfected
cells. Normal range is 3SD above mean OND signal (1438).
doi:10.1371/journal.pone.0002028.g002
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this did not reach statistical significance in this limited cohort. In
addition, the ratio of HHV6 IgG in the CSF versus serum was
elevated in a subset of UT natalizumab treated MS patients
1.460.6 (TY2, TY3, TY5, TY8, TY29, and TY21) compared to
the mean value of UT non-natalizumab treated patients (0.360.2)
or the NIH-untreated RRMS patients (0.160.1). Of particular
interest is the observation that the HHV-6 CSF/serum ratio for
TY2 and TY3 who were shown to contain HHV-6 DNA
sequences in CSF (Figure 1) was 0.9 and 1.3, respectively.
As the quantitation of serum HHV-6 IgG is based on
normalization to total serum IgG, it became evident that
natalizumab-treated MS patients had lower levels of total serum
IgG than non-natalizumab treated MS patients from the same
center (Figure 3C). The hatched area denotes the normal range of
total serum IgG (5.5–22 mg/ml) as per the manufacturer’s
instructions. Normal donors and untreated MS patients from the
NIH-cohort fell within this range with no differences demonstrated
between these two groups (Figure 3C). While the non-natalizumab
treated MS cohort from UT-Texas had lower total serum IgG, the
natalizumab-treated MS cohort had the lowest total serum IgG as
(Figure 3C). Decreased serum IgG levels are characteristic of
immunosuppression and such decreases maybe associated with
reactivation of several viruses including HHV-6 [34,35,36].
Up-regulation of JCV by HHV-6
Since reduced immune surveillance due to natalizumab
treatment may reactivate latent viruses of the CNS such as
HHV-6 it was of interest to determine if HHV-6 could be
associated with increased expression of JC virus. To investigate
whether HHV-6 could upregulate JCV expression, an SV40-
transformed human glial cell line (SVG cells) that can support the
replication of JCV at a slow rate [37] was superinfected with
HHV-6. Superinfection of these JC-infected SVG cells with HHV-6
resulted in increased production of JCV infectious particles as
measured by hemagglutination assay (Figure 4A). These results were
supported by real-time PCR for the JCV-T antigen region
(Figure 4B) and demonstrated that superinfection with HHV-6
resulted inincreased JCV copy number overtimecompared toJCV-
infected SVG cells alone. Moreover, in situ hybridization studies
(Figure 4C) also demonstrated that superinfection with HHV-6
increased the percentage of SVG cells replicating JCV DNA.
Discussion
The potential association of natalizumab treatment with
reactivation of JCV and the subsequent development of PML is
clearly a cause for concern. PML is a demyelinating brain
disorders most often seen in setting of immunusuppression such as
HIV infection and in transplant recipients. Natalizumab, an a4
integrin antagonist, blocks the binding of lymphocytes to adhesion
molecules on the vascular endothelium, which could effectively
decrease lymphocyte trafficking primarily to the gut and brain. It
has been previously demonstrated that blocking a4 integrins can
inhibit the transport of both CD4
+ and CD8
+ T cells to the CNS
[38]. Given this mode of action of natalizumab and the potential
consequence of PML in a subset of treated patients, it has been
suggested that natalizumab treatment could result in a state of
localized immune suppression in the CNS which could potentially
lead to the reactivation of latent viruses [11]. Stu ¨ve et al. recently
demonstrated that MS patients undergoing natalizumab therapy
exhibited strikingly decreased CD4:CD8 ratios in the CSF
(comparable to those of an HIV-1-infected patient cohort)
compared to MS patients not receiving natalizumab and they
attributed this to decreased migration of CD4
+ T cells into the
CNS [10,12]. Although the biological significance of this is
unknown, the results are consistent with the hypothesis that
natalizumab treatment may result in decreased immunosurveil-
lance in the CNS, potentially allowing for the reactivation of latent
viral infections. As further evidence of the ability of natalizumab to
Figure 3. Natalizumab-treated MS patients have increased
levels of serum IgG against HHV-6. (A) HHV-6 reactivity in sera of
treated University of Texas (UT) MS patients (UT-MS-Nat (+)) or not
treated with natalizumab (UT-MS-Nat (2)). Normal range same as in
figure 3. (B) HHV-6 antibody levels in CSF of other neurologic controls
(OND), encephalitis (Enceph.), NIH MS patients (NIH-MS-Nat-), MS
patients from UT not-treated or treated with natalizumab (UT-MS-Nat
(2) and UT-MS-Nat (+)). Normal range is defined as described above. (C)
Total human IgG values (mg/ml) in sera of MS cohorts and healthy
controls (ND). Significance values calculated using Mann-Whitney.
doi:10.1371/journal.pone.0002028.g003
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demonstrate a statistically significant decrease in the amount of
total serum IgG in MS patients treated with natalizumab versus
control cohorts not receiving this drug. Decreased serum IgG
levels have long been associated with immunosuppression and
opportunistic infections including viral reactivation [39,40].
If the changes in normal immune function observed following
natalizumab treatment result in decreased immune surveillance,
we hypothesize that the potential for viral reactivation would not
necessarily be limited to JCV. A number of other commensal
human viruses maintain latency in the CNS including HHV-6
[41], which has been previously been found to be present in and
around white matter lesions in PML patients [28]. Our data
suggest that HHV-6 may be reactivated in MS patients receiving
natalizumab therapy, as evidenced by the detection of viral DNA
in the CSF of 2 out of 23 natalizumab-treated patients but not in
samples from 16 untreated MS patients from the same institution.
Since failure to detect HHV-6 in CSF is a consistent finding from
untreated NIH MS patients and control patients with other
neurologic diseases, it was therefore surprising to detect the
presence of low levels of HHV-6 in MS patients treated with
natalizumab. Cell-free HHV-6 DNA is suggestive of active HHV-
6 infection while cell-associated DNA may be more commonly
associated with viral latency [22]. Moreover, the low number of
CSF samples from natalizumab-treated MS patients that tested
positive for HHV-6 sequences, although higher than what was
expected from untreated MS patients, may be a function of the
limited size of this cohort; or alternatively HHV-6 in the CSF may
not be reflective of the levels of HHV-6 in the CNS. We have
recently reported that detection of CSF HHV-6 from patients with
neurologic disease following bone marrow transplant did not
correlate with the amount of HHV-6 that could be demonstrated
in post-mortem brain sections [31]. Indeed, at times when the CSF
was either negative for HHV-6 or from samples in which HHV-6
sequences could only be amplified by nested PCR, areas of the
brain could have as many as 1 610
7 copies/10
6 cells as
determined by quantitative PCR [31]. These observations suggest
the use of caution in the interpretation of negative CSF results and
may have application to other viruses such as JCV [6]. Additional
support for the presence of HHV-6 in the natalizumab-treated MS
patients came from HHV-6 variant-specific typing. HHV-6 viral
DNA sequences obtained from the natalizumab-treated MS
patients confirmed that these sequences were specific for the
HHV-6A variant. These results are consistent with the reported
tropism of HHV-6A, which has been more often associated with
MS [18,22,25].
The detection of HHV-6 in natalizumab-treated MS patients
was further supported by serologic findings demonstrating
statistically higher levels of anti-HHV-6 IgG in serum from MS
patients undergoing natalizumab therapy compared to controls.
As there is no reliable commercially available serologic assay for
the detection of HHV-6-specific antibodies, we developed and
characterized a novel electrochemiluminescence- based method-
ology using HHV-6-infected cell lysates. This method was shown
to be highly reproducible and specific. There was no statistically
significant difference between MS serum anti-HHV-6 IgG and
controls, consistent with our previous findings [24]. In contrast,
natalizumab-treated MS patients had significantly higher levels of
Figure 4. Superinfection of human glial (SVG-JC cells) with HHV-6 can augment JCV replication. (A) Hemagglutination assay for
quantitation of JCV infectious particles in JC virus persistently infected SVG cells (SVG-JC) or SVG-JC cells super infected with HHV-6A. (B) Quantitative
real-time PCR detection of JCV DNA in JC virus persistently infected SVG cells (SVG-JC) or SVG-JC cells super infected with HHV-6A. (C) Quantitation of
in situ hybridization studies demonstrating percent of cells with replicating JCV viral DNA in SVG-JC or SVG-JC cell superinfected with HHV-6A.
doi:10.1371/journal.pone.0002028.g004
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HHV-6 is a ubiquitous b-herpesvirus acquired early in life, it was
not surprising to find that serum HHV-6 IgG is present in non-
treated MS patients and falls in the empirically determined
‘normal range’ [24]. What was unexpected, given the limitations
of such a small cohort of natalizumab treated MS patients, was the
significant increase in the number of these patients determined to
be above this normal range, both in the frequency of patients (11
of 23 natalizumab treated MS patients were above the normal
range compared to only 1 of 17 untreated MS patients) and the
magnitude of these responses (mean value of 5000 (range 0–
10,000) units in the natalizumab treated MS patients compared to
1500 units (range 0–3000). Increased antibodies to HHV-6 could
represent an immune response associated with a more recent
exposure to this virus and would be consistent with the hypothesis
that natalizumab treatment may be linked with viral reactivation.
Analysis of HHV-6 specific IgG in CSF was less informative
since CSF HHV-6 IgG was elevated (p,0.0455) in all MS groups
compared to CSF from control patients with OND. CSF from the
OND cohort gave HHV-6 specific IgG values that were defined
empirically as falling within a normal range (CSF from healthy
controls were not obtained). The utility of this novel electro-
chemiluminescence assay was again validated using CSF from
patients with encephalitis from whom a significant percentage (p
= 0.0110) was demonstrated to contain anti-HHV-6 IgG in the
CSF that correlated with CSF PCR for HHV-6 DNA (manuscript
in preparation). Increased CSF IgG to many viruses has been
reported in MS patients and we are sensitive to the over-
interpretation of what may be epiphenomenal results [42,43].
However, there was a clear impression that in the CSF of a subset
of natalizumab-treated MS patients there were higher levels of
HHV-6-specific IgG compared to untreated MS patients,
particularly those from the same center (Figure 3B), although this
did not reach statistical significance. None of the natalizumab-
treated MS patients that had positive CSF anti-HHV-6 IgG
responses had positive serum HHV-6 IgG, suggesting that the
elevated levels of HHV-6 specific IgG in CSF were not merely
spillover from peripheral blood. These results clearly demonstrate
the need to expand these observations to larger cohorts of
natalizumab-treated and control patients in order to determine if
increased intrathecal production of HHV-6 IgG is definitively
associated with natalizumab treatment.
If natalizumab treatment is associated with decreased immune
surveillance resulting in the reactivation of CNS viruses such as JCV
[44] and HHV-6 (present report), can these two viruses be causally
linked? The molecular mechanism by which JCV becomes
reactivated in immunosuppressed individuals is unknown. Previous-
ly, Winklhofer et al. demonstrated that human cytomegalovirus
(HCMV), another member of the beta- herpesvirus family, was able
to transactivate JCV via the HCMV immediate-early transactivator
2 (IE2) protein, which stimulated JCV T antigen expression
associated with JCV late gene expression [45]. Consistent with the
hypothesis that HHV-6 may be associated with up regulation of
JCV, previous studies have co-localized HHV-6 and JCV in PML
lesions by double immunohistochemical techniques [28]. Our
current work supports these results and we have also demonstrated
the presence of HHV-6 in brain lesions of PML patients by
immunohistochemistyfor HHV-6 protein, real-time PCR for HHV-
6 DNA, and sequence confirmation of HHV-6 (data not shown).
Brain lesions of natalizumab-treated patients with PML were
unavailable for analysis. The co-localization of HHV-6 in PML
lesions suggested a possible mechanism whereby HHV-6 might be
capable of reactivating JCV. This hypothesis was directly tested by
infection of the persistently JCV-infected SVG human astrocytic cell
line [37] with HHV-6. Infection of these JCV-SVG cells with HHV-
6 resulted in increased production of JCV infectious particles as well
as an increase in viral copy number measured by real-time PCR and
an increase in the total number of cells replicating JCV DNA. These
results suggest that HHV-6 infection could augment JCV replication
and, in the setting of natalizumab treatment, may have important
implications for JCV reactivation and the subsequent development
of PML. In addition, as suggested for PML reactivation in
natalizumab treated MS patients [46,47], the blockade of a4 integrin
could affect normal bone marrow physiology resulting in release of
premature lymphoid progenitor harboring latent virus(es) into the
circulation. HHV-6 has also been detected in CD34+ progenitor
cells in both normal and diseases states [48,49]. Collectively, these
findings suggest that VLA4 antagonism may promote both JC and
HHV-6 viral reactivation through impaired retention of CD34+
stem cells as well as impaired immune surveillance.
The small number of available samples from natalizumab-
treated patients is an obvious limitation to this current study but,
unfortunately, larger numbers of samples from additional cohorts
are not available at this time. Re-approval of this drug by the FDA
on June 5
th 2006 and by the regulatory agency of the European
Union on June 29
th 2006 affords new opportunities to test the
hypothesis that natalizumab treatment may be associated with an
increase in latent viruses of the CNS. These studies are currently
being planned in a multi-center trial with the Veterans
Administration. However, even with the limitation of sample size,
our present work in conjunction with previously published findings
undoubtedly represents a need for caution as patients return to
treatment with natalizumab. Prospective measures of immune
function and viral reactivation should be initiated upon return to
treatment in order to actively assess the risk of adverse reaction.
Materials and Methods
Patient Samples
Serum and CSF from 23 relapsing-remitting MS patients [50]
treated with natalizumab (22 who received natalizumab in clinical
trials, 1 patient who received natalizumab after its approval) and
17 MS patients who had not received natalizumab were obtained
from the University of Texas Southwestern Medical Center at
Dallas Multiple Sclerosis Center (Table 1). Serum and CSF
samples from MS patients, healthy volunteers, and BMT patients
were collected at the NIH Clinical Center. CSF from patients with
encephalitis of unknown origin was obtained from the California
Health Department. CSF was also obtained from 9 patients
undergoing allogeneic BMT as described [31] and from patients
with other neurologic diseases evaluated at the NIH clinical center
(Table S1). Informed consent was obtained from all patients, and
the respective Institutional Review Boards approved all study
procedures.
Details on the patient cohort from UT Southwestern and Texas
Neurology are published elsewhere [10,12]. Patients received a
median of 30 doses of natalizumab (range: 1–41). The median
interval between the last natalizumab treatment and sampling of
CSF and peripheral blood was 34 days (range: 5–45 days). The
mean time of disease duration was 8 years (63.8 years). The
median time since last relapse from when the sample was taken
was 2.63 years with a range from 0.17–3.04 years. The mean
number of Gd-enhancing lesions was 0 (60). The NIH RRMS
group had a median disease duration of 4.9 years with a range
from 2 months to 28 years. The median time since last relapse
from when the sample was taken was 0.42 years with a range from
0–2.75 years. The mean number of Gd-enhancing lesions was
3(66) with a range from 0–29.
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sequencing
DNA was isolated using extraction kits according to manufac-
turers’ instructions [51] and PCR amplified as described [52].
PCR products were purified using the Qiagen MinElute PCR
Purification Kit (Qiagen, CA) and sequenced with Dye-Termina-
tors (Perkin Elmer) for HHV-6 subtyping.
Detection of anti-HHV-6 IgG and total human IgG
Antibodies against HHV-6 proteins were detected using
electrochemiluminescence technology (MSD, Gaithersburg, MD)
developed in our laboratory. Characterization of assay sensitivity
and specificity are described in the supplemental information
(Text S1, Figure S1). HHV-6B or mock-infected (SupT1) cell
lysate prepared as described [25] was spotted onto plates (L17XB)
and allowed to dry at room temperature (RT). 200 ml of Blocker A
solution was added to each well and plates were blocked on a
shaker for 1 hour at RTand then washed twice with 300 ml PBS.
Serum/CSF were diluted in MSD Antibody Diluent and added to
plates in 25 ml per well and incubated on shaker at RT for 1 hour
and washed twice with PBS. Samples were tested in duplicate.
25 ml Sulfo-Tag
TM labeled goat anti-human IgG (1 mg/ml) was
added to each well, incubated and washed as described above.
150 ml MSD Read Buffer T was added to each well before analysis
with a MSD PR400 plate reader. Total human IgG was measured
in duplicate using the Easy-TiterH IgG Assay Kit (Pierce)
according to the manufacture’s protocol. The range of detection
is between 15–300 ng/ml. Nonparameteric Mann-Whitney U-test
was used for group analysis in this study to obtain a more
conservative evaluation of statistical significance.
HHV-6 infection of SVG cells
SVG cells [37], a human fetal astroglial cell line chronically
infected with JCV (Mad-4 strain) were seeded onto 6 well plates
overnight. Cells were washed twice with PBS followed by incubation
for 3 hours at 37uCi n5 %C O 2 with cell-free HHV-6 supernatant.
Cells werewashed with PBS and replaced with medium. Cellculture
JCV eplication was assessed by CPE, hemagglutination, in situ
hybridization and quantitative PCR [53,54,55] and Mock infections
were carried out using supernatant from uninfected SupT-1.
Infections of each HHV-6 variant were performed twice.
Supporting Information
Text S1 Characterization of a novel electrochemiluminescece
assay for detection of HHV-6 using monoclonal anti-HHV-6
antibodies.
Found at: doi:10.1371/journal.pone.0002028.s001 (0.04 MB
DOC)
Figure S1 Characterization of a novel electrochemiluminescece
assay for detection of HHV-6 using monoclonal anti-HHV-6
antibodies. (A) HHV-6B lysate (Z29 infected SupT-1 cells)
reactivity with HHV-6 specific p41 monoclonal antibody.
Reactivity is measured as photon emission. (B) HHV-6B lysate
(Z29 infected SupT-1 cells) reactivity with larger panel of HHV-6
specific monoclonal antibodies except for the HHV-6A specific
anti-p41/38 monoclonal antibody. (C) Lysate of uninfected SupT-
1 cells reactive with the panel of HHV-6 specific antibodies. (D)
Capture-detection assay using HHV-6 variant B lysate with the
indicated monoclonal antibodies. (E) Capture-detection assay
using HHV-6 variant A lysate with the indicated monoclonal
antibodies. (F) Reactivity of 14 healthy control sera (dotted lines)
against HHV-6B lysate. Solid black line illustrates the average
antibody reactivity against HHV-6 in 14 healthy controls. (G) Sera
from two natalizumab-treated patients TY20 and TY11 were
tested for antibody reactivity against HHV-6B antigens at various
dilutions as indicated. For panels D-G, reactivity is measured as
photon emission on virus infected lysate minus photon emission on
uninfected cells.
Found at: doi:10.1371/journal.pone.0002028.s002 (1.55 MB TIF)
Table S1 List of other neurologic diseases
Found at: doi:10.1371/journal.pone.0002028.s003 (0.03 MB
DOC)
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